Previous close | 0.0900 |
Open | 0.0900 |
Bid | 0.0850 x N/A |
Ask | 0.1000 x N/A |
Day's range | 0.0900 - 0.1000 |
52-week range | 0.0800 - 0.3000 |
Volume | |
Avg. volume | 14,984 |
Market cap | 10.025M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1800 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ARCpoint ( CVE:ARC ) Full Year 2023 Results Key Financial Results Revenue: US$6.67m (down 39% from FY 2022). Net loss...
Greenville, South Carolina, April 29, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to consumer (“DTC”) clinical lab testing services, announces that it will host a conference call at 4pm Eastern time, Wednesday, May 1, 2024 to review the Company’s 2023 full year and fourth quarter, ending December 31, 2023 results. The dial-in number for the conference call is as foll
Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of US$1,100,000, through the sale of 11,000,000 Class A subordinate voting shares of the Company (each, a “Share”) at a price of US$0.10 per Share. The net proceeds from t